The Potential of Psychedelics for End of Life and Palliative Care.
Current topics in behavioral neurosciences – January 01, 2022
Source: PubMed
Summary
Psychedelics, particularly psilocybin, are emerging as a promising avenue for improving End of Life and Palliative care. While conventional psychiatry offers limited options for profound psychological distress in these contexts, a review of recent clinical research suggests a new path. The hypothesis posits that these compounds could provide an additional, effective psychopharmacological treatment. Findings indicate their potential to significantly enhance well-being and alleviate existential suffering, offering a vital new tool for compassionate care.
Abstract
End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these contexts remain limited. In particular, psychological factors such as depression, existential distress, and well-being remain challenging to address with current medications. Here, we review recent research on the use of psychedelics in clinical settings with a particular focus on patients with life-threatening diagnoses. We propose that psychedelics may provide clinicians with an additional psychopharmacological treatment in the context of end of life and palliative care.